Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations-Reference-Cited by-同舟云学术

Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations

Published:2023-09-01 Issue:21 Volume:29 Page:4317-4319
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Rolfo Christian¹^ORCID,Del Re Marzia¹²^ORCID,Russo Alessandro³^ORCID

Affiliation:

1. 1Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.

2. 2Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

3. 3Department of Onco-Hematology, Papardo Hospital, Messina, Italy.

Abstract

Summary Trastuzumab deruxtecan (T-DXd) is reshaping the therapeutic landscape of HER2-positive tumors. A recent article reports on the preclinical activity of the combination of T-DXd plus adavosertib, WEE1 kinase inhibitor, which promises to expand the use of this antibody–drug conjugate in HER2-positive tumors with CCNE1 coamplification. See related article by DiPeri et al., p. 4385

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-23-1700/3362039/ccr-23-1700.pdf

Reference19 articles.

1. Adavosertib enhances antitumor activity of trastuzumab deruxtecan in HER2-expressing cancers;DiPeri;Clin Cancer Res,2023

2. Optimizing the safety of antibody-drug conjugates for patients with solid tumours;Tarantino;Nat Rev Clin Oncol,2023

3. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study;Banerji;Lancet Oncol,2019

4. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer;Modi;N Engl J Med,2022

5. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer;Cortés;N Engl J Med,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate;Expert Opinion on Investigational Drugs;2024-07-09